Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Hong-Lee Yu who wrote (758)	10/6/1998 9:23:00 AM
From: Harold Engstrom	Read Replies (2) \| Respond to of 1686

Hong-Lee Yu, It looks like our estimates were not too far off, as long as Biogen's conservative accrual of royalties yields a carryover of earnings into next quarter. Truly astounding revenue growth. Earlier and later treatment of MS, aided by new diagnostic tools, would really boost Avonex sales over the next couple of years. Maybe the Avonex market is much bigger than anyone even now perceives it to be. Pipeline news was great. Most important to me was the addition of another promising compound to the pipeline. That said, LFA3TIP and 5C8 sure seem to have Joe Davies' blessing. Very nice quarter. Excellent story for the future.